Loading...
Xeris Biopharma Q1 2025 Earnings Report
Xeris Biopharma reported record first quarter 2025 financial results.
Key Takeaways
Xeris Biopharma reported a strong start to 2025 with record first-quarter revenue of over $60 million, a 48% year-over-year increase, driven by significant growth in Recorlev revenue. The company also tightened its full-year total revenue guidance.
Total revenue increased 48% year-over-year to $60.1 million.
Recorlev revenue grew 141% year-over-year to $25.5 million, driven by a 124% increase in average number of patients.
Net loss for the first quarter was $9.2 million, or ($0.06) per share.
Adjusted EBITDA was positive $4.4 million, an improvement of $8.4 million compared to the first quarter of 2024.
Xeris Biopharma
Xeris Biopharma
Xeris Biopharma Revenue by Segment
Revenue by Segment
Recorlev Revenue
CapyFin.comGvoke Revenue
CapyFin.comKeveyis Revenue
CapyFin.comRoyalty, Contract & Other Revenue
CapyFin.com Forward Guidance
Xeris Biopharma tightened its full-year total revenue 2025 guidance to $260 million to $275 million, reflecting strong continued momentum and confidence in the business.
Positive Outlook
- Tightened full-year total revenue 2025 guidance to $260 million to $275 million.
- Revision from previous range of $255 million to $275 million underscores success of strategic initiatives.
- Commitment to driving sustainable growth and delivering value to patients and shareholders.
- Expectation of continued strong demand for Recorlev.
- Confidence in the business's ability to maintain momentum.
Challenges Ahead
- No specific negative forward guidance points were mentioned in the provided text.
- No specific negative forward guidance points were mentioned in the provided text.
- No specific negative forward guidance points were mentioned in the provided text.
- No specific negative forward guidance points were mentioned in the provided text.
- No specific negative forward guidance points were mentioned in the provided text.